Working… Menu

Low Dose Versus Aggressive Inhibition of the Renin-Angiotensin-Aldosterone (RAS) to Treat Microalbuminuria (END-IT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00907374
Recruitment Status : Completed
First Posted : May 22, 2009
Results First Posted : March 30, 2012
Last Update Posted : March 30, 2012
Information provided by (Responsible Party):
Mayer Davidson, Charles Drew University of Medicine and Science

Brief Summary:
The objective of the study is to assess the effect of standard versus aggressive inhibition of the renin-angiotensin system (RAS)in type 2 diabetic patients with microalbuminuria (MA) on; a)progression of microalbuminuria, b)estimated glomerular filtration rate (eGFR), c)endothelial dysfunction (measured by post-hyperemia arterial tonometry) and d)the slowing of the progression of atherosclerotic disease (measured by carotid intima media thickness [CIMT]).

Condition or disease Intervention/treatment Phase
Microalbuminuria Drug: benazepril Not Applicable

Detailed Description:

Diabetic patients with confirmed MA (50-300 mg albumin per g creatinine) on a morning spot urine sample were entered into a one to three month run-in phase before randomization. (50 mg/g was used as the lower limit to allow room for improvement to reach normal.) Since hypertension and uncontrolled hyperglycemia will cause MA, blood pressure (BP) and hemoglobin A1c (AIC) levels were reduced to <130/80 mm Hg and <8.0%, respectively, during this period. All patients had been on various doses of an angiotensin converting enzyme inhibitor (ACE-I) which were reduced to 10 mg benazepril and BP controlled with other classes of anti-hypertensive drugs (except for angiotensin receptor blockers [ARB's]). Glycemia was treated with intensification of their current therapy. MA and BP were measured monthly.

When goal levels of BP and AIC were achieved and MA was still present, patients were randomized to either low dose RAS inhibition (10 mg benazepril) (Standard) or aggressive inhibition of the RAS (Aggressive). MA continued to be measured monthly and the progressive increase in doses of an ACE-I and an ARB was as follows. Benazepril (the ACE-I) - 10 mg to 20 mg to 40 mg to adding losartan (the ARB) -25 mg to 50 mg to 100 mg to increasing benazepril to 80 mg with the goal of returning albumin excretion to normal. Other classes of drugs were reduced as necessary to keep systolic BP > 100 mm Hg. Serum creatinine and potassium[K+] were measured monthly, AIC levels every 3 months and CIMT by ultrasound and endothelial function by post hyperemia and nitroglycerine (NTG) - induced peripheral artery tonometry (PAT) via finger plethysmography every six months.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 46 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Early Nephropathy Study in Diabetes With Inhibitory Renin-Angiotensin-Aldosterone System Therapy (END-IT)
Study Start Date : July 2005
Actual Primary Completion Date : April 2009
Actual Study Completion Date : April 2009

Resource links provided by the National Library of Medicine

Drug Information available for: Benazepril

Arm Intervention/treatment
Active Comparator: Low dose inhibition of RAS
Standard low dose inhibition of the RAS with 10 mg of benazepril orally daily to treat microalbuminuria
Drug: benazepril
benazepril 10 mg orally once daily
Other Name: Lotensin

Experimental: Agressive inhibition of the RAS
40-80 mg benazepril plus 25-100 mg losartan both orally once or twice daily
Drug: benazepril
40-80 mg benazepril plus 25-100 mg losartan orally once or twice daily
Other Names:
  • Lotensin
  • Cozaar

Primary Outcome Measures :
  1. Microalbuminuria Reported as Urinary Albumin:Creatinine Ratio [ Time Frame: 3 to 36 months ]
    Average of ratio for all participants during the 3-36 months of the study

Secondary Outcome Measures :
  1. Estimated Glomerular Filtration Rate [ Time Frame: 3 to 36 months ]
    This is an average for all participants during the 3-36 month study period

  2. Carotid Artery Intima Thickness [ Time Frame: 6 to 36 months ]
    Thickness of intima of right carotid artery; average of all particpants from 6-36 months of study

  3. Endothelial Dysfunction [ Time Frame: 6 to 36 months ]
    Post hyperemia increase in blood flow - fold increase from before and after occluding BP; values are mean of all participants in 6-36 months of study period.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Males and females, age 18-70
  • Subjects with diabetic renal disease as defined by spot urine albumin - creatinine ratio 30-300mg/g and estimated glomerular filtration rate of >60 ml/min

Exclusion Criteria:

  • Intake of non-steroidal anti-inflammatory agents (NSAIDs) more than 15 days/month, excluding aspirin.
  • Inability to discontinue NSAIDs or aspirin for 5 days prior to GFR measurement.
  • History of severe adverse reaction to any of the randomized drugs required for use in the protocol or contraindication of their use.
  • Participation in another intervention study.
  • Pregnancy or likelihood of becoming pregnant during the study period; lactation
  • Clinical and laboratory evidence of any renal disease other than diabetic nephropathy.
  • History of drug abuse in the past 2 years, including narcotics, cocaine or alcohol (> 21 drinks per week). Serious systemic disease that might influence survival or the course of renal disease. (Chronic oral steroid therapy is exclusion, but steroid-containing nasal sprays are not. Inactive sarcoidosis is not an exclusion).
  • History of malignant or accelerated hypertension within 6 months prior to study entry; previous chronic peritoneal or hemodialysis or renal transplantation. Known secondary causes of hypertension. Spot urine albumin - creatinine ratio exceeding 300 (mg/g)
  • Serum potassium level > 5.5 mEq/L for those not on ACE inhibitors during Baseline, or serum potassium level > 5.9 mEq/L for those on ACE inhibitors during Baseline.

Leukopenia < 2,500/mm3 at screening and confirmed at the end of Baseline.

  • Doubt that the participant will be able to adhere to medications or comply with the protocol visit schedule
  • Arm Circumference > 52 cm, which precludes measuring blood pressure with the "thigh" blood pressure cuff. Arm length such that if the cuff circumference extended into the antecubital space so that the cuff interfered with placement of the stethoscope over the brachial artery for blood pressure measurement
  • Clinical evidence of lead intoxication. Clinical evidence of congestive heart failure, current or within the preceding six months. Ejection fraction below 35% measured by any method. Heart block greater than first degree or any other arrhythmia that contraindicated the use of any of the primary BP drugs.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00907374

Layout table for location information
United States, California
Charles Drew University
Los Angeles, California, United States, 90059
Sponsors and Collaborators
Charles Drew University of Medicine and Science
Layout table for investigator information
Principal Investigator: Naureen Taureen, MD Charles Drew University
Study Director: Mayer B. Davidson, MD Charles Drew University
Layout table for additonal information
Responsible Party: Mayer Davidson, Professor of Medicine, Charles Drew University of Medicine and Science Identifier: NCT00907374    
Other Study ID Numbers: IRB# 04-09-772
U54RR014616 ( U.S. NIH Grant/Contract )
First Posted: May 22, 2009    Key Record Dates
Results First Posted: March 30, 2012
Last Update Posted: March 30, 2012
Last Verified: March 2012
Keywords provided by Mayer Davidson, Charles Drew University of Medicine and Science:
Carotid intima media thickness
Endothelial dysfunction
Renin angiotensin system
Diabetic nephropathy
Additional relevant MeSH terms:
Layout table for MeSH terms
Angiotensin-Converting Enzyme Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antihypertensive Agents